Verrica Pharmaceuticals Inc. Unbilled Receivables, Current
Verrica Pharmaceuticals Inc. (VRCA) had Unbilled Receivables, Current of $46.00 thousand as of 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:UnbilledReceivablesCurrent · last filed 2025-05-13
- 2025-03-31: Unbilled Receivables, Current $46.00K.
- 2024-12-31: Unbilled Receivables, Current $29.00K.
- 2024-09-30: Unbilled Receivables, Current $84.00K.
- 2024-06-30: Unbilled Receivables, Current $182.00K.
| Period end | Unbilled Receivables, Current |
|---|---|
| 2025-03-31 | $46.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $29.00K 10-Q · filed 2025-05-13 |
| 2024-09-30 | $84.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $182.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $592.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $168.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $126.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $173.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $56.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $99.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $419.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $218.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $431.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |